CLB vs. BIO
CLB (Core Laboratories NV) and BIO (Bio-Rad Laboratories, Inc.) are both stocks. CLB operates in Oil & Gas Equipment & Services (Energy), while BIO operates in Medical Devices (Healthcare). Over the past 10 years, CLB returned -19.93%/yr vs 7.32%/yr for BIO. At a 0.19 correlation, their price movements are largely independent.
Performance
CLB vs. BIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CLB achieves a -26.48% return, which is significantly lower than BIO's -7.22% return. Over the past 10 years, CLB has underperformed BIO with an annualized return of -19.93%, while BIO has yielded a comparatively higher 7.32% annualized return.
CLB
- 1D
- 0.68%
- 1M
- -17.23%
- YTD
- -26.48%
- 6M
- -28.96%
- 1Y
- -4.88%
- 3Y*
- -19.72%
- 5Y*
- -22.36%
- 10Y*
- -19.93%
BIO
- 1D
- -0.47%
- 1M
- -2.30%
- YTD
- -7.22%
- 6M
- -7.79%
- 1Y
- 18.74%
- 3Y*
- -8.40%
- 5Y*
- -14.79%
- 10Y*
- 7.32%
CLB vs. BIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CLB Core Laboratories NV | -26.48% | -7.12% | -1.76% | -12.72% | -8.97% | -15.73% | -29.05% | -34.35% | -44.49% | -6.83% |
BIO Bio-Rad Laboratories, Inc. | -7.22% | -7.77% | 1.74% | -23.21% | -44.35% | 29.61% | 57.54% | 59.34% | -2.70% | 30.94% |
Correlation
The correlation between CLB and BIO is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Sep 21, 1995 | 0.19 |
Fundamentals
CLB:
$542.28M
BIO:
$7.58B
CLB:
$0.67
BIO:
$6.24
CLB:
17.67
BIO:
45.01
CLB:
0.98
BIO:
0.41
CLB:
1.05
BIO:
2.93
CLB:
1.97
BIO:
1.11
CLB:
$524.73M
BIO:
$2.59B
CLB:
$73.89M
BIO:
$1.34B
CLB:
$70.89M
BIO:
$746.20M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CLB vs. BIO — Risk / Return Rank
CLB
BIO
CLB vs. BIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Core Laboratories NV (CLB) and Bio-Rad Laboratories, Inc. (BIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLB | BIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.54 | ||
| Sortino ratioReturn per unit of downside risk | -0.70 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.13 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | -0.12 | 0.65 | -0.77 |
| Martin ratioReturn relative to average drawdown | -0.30 | 1.51 | -1.82 |
Loading charts...
Drawdowns
CLB vs. BIO - Drawdown Comparison
The maximum CLB drawdown since its inception was -95.78%, which is greater than BIO's maximum drawdown of -83.64%. Use the drawdown chart below to compare losses from any high point for CLB and BIO.
Loading charts...
Drawdown Indicators
| CLB | BIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.78% | -83.64% | -12.14% |
Max Drawdown (1Y)Largest decline over 1 year | -41.81% | -28.86% | -12.95% |
Max Drawdown (3Y)Largest decline over 3 years | -64.29% | -48.76% | -15.53% |
Max Drawdown (5Y)Largest decline over 5 years | -76.91% | -73.77% | -3.14% |
Max Drawdown (10Y)Largest decline over 10 years | -93.50% | -73.77% | -19.73% |
Current DrawdownCurrent decline from peak | -93.70% | -65.96% | -27.74% |
Average DrawdownAverage peak-to-trough decline | -41.43% | -27.76% | -13.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 16.12% | 12.41% | +3.71% |
Volatility
CLB vs. BIO - Volatility Comparison
Core Laboratories NV (CLB) has a higher volatility of 13.86% compared to Bio-Rad Laboratories, Inc. (BIO) at 9.37%. This indicates that CLB's price experiences larger fluctuations and is considered to be riskier than BIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CLB | BIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.86% | 9.37% | +4.49% |
Volatility (6M)Calculated over the trailing 6-month period | 34.54% | 28.73% | +5.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 58.56% | 41.22% | +17.34% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 53.80% | 37.34% | +16.46% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 55.03% | 34.07% | +20.96% |
Dividends
CLB vs. BIO - Dividend Comparison
CLB's dividend yield for the trailing twelve months is around 0.34%, while BIO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIO Bio-Rad Laboratories, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CLB Core Laboratories NV | 0.34% | 0.25% | 0.23% | 0.23% | 0.20% | 0.18% | 1.06% | 5.84% | 3.69% | 2.01% | 1.83% | 2.02% |
Financials
CLB vs. BIO - Financials Comparison
This section allows you to compare key financial metrics between Core Laboratories NV and Bio-Rad Laboratories, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CLB vs. BIO - Profitability Comparison
CLB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Core Laboratories NV reported a gross profit of 0.00 and revenue of 121.80M. Therefore, the gross margin over that period was 0.0%.
BIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bio-Rad Laboratories, Inc. reported a gross profit of 309.40M and revenue of 592.10M. Therefore, the gross margin over that period was 52.3%.
CLB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Core Laboratories NV reported an operating income of 1.89M and revenue of 121.80M, resulting in an operating margin of 1.6%.
BIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bio-Rad Laboratories, Inc. reported an operating income of 34.10M and revenue of 592.10M, resulting in an operating margin of 5.8%.
CLB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Core Laboratories NV reported a net income of -789.00K and revenue of 121.80M, resulting in a net margin of -0.7%.
BIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bio-Rad Laboratories, Inc. reported a net income of -527.10M and revenue of 592.10M, resulting in a net margin of -89.0%.
Frequently Asked Questions
CLB and BIO have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLB has higher volatility (13.86%) compared to BIO (9.37%). In terms of maximum drawdown, CLB dropped -95.78% vs BIO's -83.64%.
BIO currently has the higher Sharpe Ratio (0.46 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CLB and BIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer